<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of giant cell arteritis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of giant cell arteritis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of giant cell arteritis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carlo Salvarani, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francesco Muratore, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth J Warrington, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Trobe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Giant cell arteritis (GCA, also known as Horton disease, cranial arteritis, and temporal arteritis) is categorized as a vasculitis of large- and medium-sized vessels because it can involve the aorta and great vessels. It also shares some histopathologic features with Takayasu arteritis, the other major "large vessel" (LV) vasculitis. Systemic symptoms are common in GCA and vascular involvement can be widespread, causing stenosis and aneurysm of affected vessels. It is the targeting of the tiny muscular arteries from cranial branches of the aortic arch, however, that gives rise to many of the most characteristic symptoms of GCA. The most feared complication, visual loss, is one potential consequence of the cranial phenotype of GCA.
        </p>
        <p>
         The clinical manifestations of GCA will be reviewed here. The pathogenesis, diagnosis, and treatment of this disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8234.html" rel="external">
          "Pathogenesis of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">
          "Treatment of giant cell arteritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Giant cell arteritis (GCA) is the most common idiopathic systemic vasculitis [
         <a href="#rid1">
          1
         </a>
         ]. In the United States, the lifetime risk of developing GCA has been estimated at approximately 1 percent in women and 0.5 percent in men [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The greatest risk factor for developing GCA is aging. The disease almost never occurs before age 50 years, and its incidence rises steadily thereafter, peaking between the ages of 70 to 79 [
         <a href="#rid3">
          3
         </a>
         ], with over 80 percent of patients older than 70 years of age [
         <a href="#rid4">
          4,5
         </a>
         ]. One study found the mean age at incidence of GCA to be 76.7 years [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         In addition to age, ethnicity is a major risk factor for GCA. The highest incidence figures are found in Scandinavian countries and among Americans of Scandinavian descent. In Olmsted County, Minnesota, the annual incidence of GCA was 15 per 100,000 persons over the age of 50, similar to that in Scandinavian countries [
         <a href="#rid3">
          3,7
         </a>
         ]. This similarity probably reflects shared genetic risk factors, as many of the inhabitants of Olmsted County during the period of study were descended from Scandinavians and northern Europeans. In Southern Europe and Mediterranean countries, incidence rates are lower, with less than 10 per 100,000 persons over the age of 50 [
         <a href="#rid5">
          5,8,9
         </a>
         ]. GCA is less common in Latin American, Asian, Arab, and African American populations, though formal data on these populations are scant [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Autopsy studies suggest that GCA is more frequent than reported in studies of clinically diagnosed cases. A study from Sweden found arteritis in 1.6 percent of 889 postmortem cases in which sections of the temporal artery and two transverse sections of the aorta were made [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         As with many systemic rheumatic diseases, females are affected more frequently than males, in a ratio of almost 3:1 in populations of Scandinavian descent [
         <a href="#rid3">
          3
         </a>
         ]. The ratio of women to men is lower in Mediterranean countries. Familial aggregation of GCA is not unusual [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8234.html" rel="external">
          "Pathogenesis of giant cell arteritis", section on 'Predisposing factors'
         </a>
         .)
        </p>
        <p>
         Most studies have found that life expectancy is not, or is only marginally, reduced in GCA [
         <a href="#rid13">
          13-15
         </a>
         ], with the exception of the subset of patients who develop aortic aneurysm or aortic dissection or rupture [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="local">
          'Large vessel involvement'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H517922934">
         <span class="h1">
          ASSOCIATION WITH POLYMYALGIA RHEUMATICA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polymyalgia rheumatica (PMR) is characterized by aching and morning stiffness about the shoulder and hip girdles, in the neck, and in the torso. PMR is closely linked to giant cell arteritis (GCA), occurring in approximately 40 to 50 percent of patients with GCA [
         <a href="#rid17">
          17
         </a>
         ]. Conversely, GCA is found in approximately 10 percent of patients with PMR. (See
         <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">
          "Clinical manifestations and diagnosis of polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p>
         The precise nature of the relationship between GCA and PMR is not completely understood. In some patients, symptoms and signs of the two conditions occur simultaneously, while in others they appear separately over time.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The onset of symptoms in giant cell arteritis (GCA) tends to be subacute, but abrupt presentations over a few days can occur. Although many of the clinical manifestations of GCA are nonspecific, some characteristic findings strongly suggest the diagnosis  (
         <a class="graphic graphic_table graphicRef54634" href="/z/d/graphic/54634.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Constitutional symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic symptoms associated with GCA are frequent and include fever, fatigue, and weight loss. Fevers occur in up to one-half of patients with GCA and are usually low-grade. However, in approximately 15 percent of patients, fevers exceed 39ºC (102.2ºF), often leading to misdiagnoses of infections [
         <a href="#rid18">
          18
         </a>
         ]. One study found that one in six fevers of unknown origin in older adults was due to GCA [
         <a href="#rid19">
          19
         </a>
         ]. Anorexia and weight loss are usually minor, but, like fever, may be significant [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         We estimate that in approximately 10 percent of patients with GCA, constitutional symptoms and/or laboratory evidence of inflammation dominate the clinical presentation and may be the only clues to the diagnosis (see
         <a class="local">
          'Laboratory findings'
         </a>
         below). Thus, in an older adult with fever or constitutional symptoms not explained by an initial evaluation for infection or malignancy, a diagnosis of GCA warrants consideration.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Headache
         </span>
         <span class="headingEndMark">
          —
         </span>
         Headache is a common presentation of GCA, occurring in more than two-thirds of patients [
         <a href="#rid17">
          17,21
         </a>
         ]. The quality of headache in GCA, apart from the occasional specific complaint of tenderness of the scalp to touch, has no defining characteristics. Its salient feature is that it is new. Although headache is the chief complaint in many patients presenting with GCA, in some this symptom must be elicited by direct questioning.
        </p>
        <p>
         Classically, headaches due to GCA are located over the temples, but they can also be frontal, occipital, unilateral, or generalized. The headaches can progressively worsen, wax and wane, or sometimes recede before treatment is started.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Jaw claudication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nearly one-half of GCA patients experience jaw claudication, a symptom that involves mandibular pain or fatigue brought on by mastication and relieved by stopping. In some cases, patients note a trismus-like symptom, with either perceived or actual limitation of temporomandibular joint excursion. Claudication symptoms occasionally affect the tongue during eating or with repeated swallowing.
        </p>
        <p>
         In an analysis of the diagnostic value of temporal artery biopsies, which correlated positive biopsies with clinical symptoms, jaw claudication was the symptom most highly associated with a positive biopsy [
         <a href="#rid22">
          22
         </a>
         ]. Among 134 patients who underwent temporal artery biopsy, jaw claudication was present in 54 percent of those with positive biopsies, compared with only 3 percent of those whose biopsies were negative.
        </p>
        <p class="headingAnchor" id="H1246610284">
         <span class="h2">
          Ocular involvement
         </span>
        </p>
        <p class="headingAnchor" id="H214773186">
         <span class="h3">
          Transient visual loss (amaurosis fugax)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient monocular (and, rarely, binocular) impairment of vision can be an early manifestation of GCA. With transient monocular visual loss (TMVL), affected patients typically note an abrupt partial field defect or temporary curtain effect in the field of vision of one eye. Patients with polymyalgia rheumatica (PMR) or GCA are often sensitized to the potential for vision loss. It can be useful in the course of evaluating the possible significance of a reported visual disturbance to inquire if the patient tried to cover each eye; explicit monocular visual loss would heighten concern for GCA. Transient visual loss can be a harbinger of permanent visual loss, and thus mandates urgent attention in a patient with suspected PMR or GCA. (See
         <a class="medical medical_review" href="/z/d/html/5245.html" rel="external">
          "Amaurosis fugax (transient monocular or binocular visual loss)", section on 'Other causes of ischemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H517923029">
         <span class="h3">
          Permanent vision loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unquestionably the most feared complication of GCA remains that of permanent loss of vision, which commonly is painless and sudden, may be partial or complete, and may be unilateral or bilateral. Even in the era of effective therapy, the incidence of permanent partial or complete loss of vision in one or both eyes due to GCA as described from multiple centers has ranged from 15 to 20 percent of patients [
         <a href="#rid23">
          23-28
         </a>
         ]; a more recent report found a lower incidence of 8.2 percent [
         <a href="#rid29">
          29
         </a>
         ]. Though permanent visual loss may be preceded by single or multiple episodes of transient visual loss, it can also occur with devastating swiftness. Once established, visual loss is rarely reversible [
         <a href="#rid30">
          30
         </a>
         ]. Moreover, it has been estimated that within one week, further loss of vision in the unaffected eye ensues in 25 to 50 percent of untreated patients [
         <a href="#rid31">
          31
         </a>
         ]. If vision is intact, however, the prompt initiation of adequate glucocorticoid treatment virtually abolishes the subsequent risk of sight loss. If there is preexisting visual loss, such treatment will markedly reduce the risk of further deterioration, but will not improve established visual loss [
         <a href="#rid32">
          32
         </a>
         ]. Fast-track clinics for the diagnosis of GCA might help to identify patients sooner and therefore initiate adequate treatment before complications such as blindness occur. (See
         <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">
          "Treatment of giant cell arteritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H214773080">
         <span class="h4">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         To date, no definite ways of stratifying risk factors for permanent visual loss in GCA have been established. Age, hypertension, thrombocytosis, jaw claudication, and other features have been proposed as risk factors, but in most studies, only prior transient visual loss has been identified as the strongest predictor for subsequent permanent visual loss [
         <a href="#rid25">
          25-28,32,33
         </a>
         ].
        </p>
        <p>
         Several studies have found a reduced risk of visual complications in patients with GCA who have heightened inflammatory status, as indicated by fever, elevations of the acute phase reactants, and anemia [
         <a href="#rid34">
          34-36
         </a>
         ]. Pretreatment levels of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in GCA, for example, correlate inversely with the risk of visual symptoms. A strong inflammatory response could protect against ischemic lesions by two means: first, patients with pronounced inflammatory features might be seen sooner in the clinic and thus receive more prompt treatment, and, second, interleukin (IL) 6, a key inflammatory cytokine, is endowed with angiogenic properties, and might therefore counteract arteritis-induced ischemia [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H368146369">
         <span class="h4">
          Causes of vision loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         Permanent loss of vision in GCA results from arteritic anterior ischemic optic neuropathy (AION), central or branch retinal artery occlusion (CRAO/BRAO), posterior ischemic optic neuropathy (PION), or, rarely, cerebral ischemia [
         <a href="#rid37">
          37-39
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anterior ischemic optic neuropathy
         </strong>
         – At least 85 percent of cases of vision loss in patients with GCA are caused by AION. The ischemic insult in arteritic AION is typically the consequence of occlusion of the posterior ciliary artery, a branch of the ophthalmic artery from the internal carotid artery, and the main arterial supply to the optic nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Only a small percentage of the total occurrences of AION are due to GCA. Most AION is nonarteritic and commonly secondary to atherosclerotic disease [
         <a href="#rid40">
          40
         </a>
         ]. Approximately 40 percent of patients who suffer nonarteritic AION regain some amount of visual acuity, in contrast to visual loss due to GCA, which is more often massive and irreversible [
         <a href="#rid28">
          28
         </a>
         ]. The concurrence of AION with occlusion of the cilioretinal artery, an anatomic variant present in approximately one-fifth of the population, is almost always due to arteritic disease [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central retinal artery occlusion
         </strong>
         – CRAO is a less common cause of visual loss in GCA. Atherosclerosis, especially involving the carotid arteries, accounts for the bulk of cases of CRAO. BRAOs, though reported, are unusual in GCA. (See
         <a class="medical medical_review" href="/z/d/html/5236.html" rel="external">
          "Central and branch retinal artery occlusion", section on 'Other inflammatory disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5236.html" rel="external">
          "Central and branch retinal artery occlusion", section on 'Central retinal artery occlusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Posterior ischemic optic neuropathy
         </strong>
         – PION, which results from interruption of blood flow to the retrobulbar portion of the optic nerve, is an unusual occurrence in GCA, but should be considered in the differential diagnosis of PION presenting in an older adult. (See
         <a class="medical medical_review" href="/z/d/html/5232.html" rel="external">
          "Posterior ischemic optic neuropathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral ischemia
         </strong>
         – Homonymous hemianopia is a visual field defect involving either the two right or the two left halves of the visual fields of both eyes. The most common cause in GCA is an occipital lobe infarction resulting from a lesion in the vertebrobasilar circulation. In rare cases, bilateral occipital lobe involvement leads to bilateral homonymous field defects and to the development of cortical blindness (see
         <a class="medical medical_review" href="/z/d/html/5247.html" rel="external">
          "Homonymous hemianopia"
         </a>
         ). GCA rarely affects the intracerebral vessels, which is discussed further below. (See
         <a class="local">
          'Central nervous system involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1310286917">
         <span class="h3">
          Ophthalmic syndromes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diplopia
         </strong>
         – Extraocular motility disorders occur in approximately 5 percent of patients with GCA [
         <a href="#rid42">
          42
         </a>
         ]. In the context of other symptoms suggestive of GCA, diplopia has a high specificity for the disease [
         <a href="#rid43">
          43
         </a>
         ]. Diplopia, which is usually transient, can result from ischemia to almost any portion of the oculomotor system, including the brainstem, oculomotor nerves, and the extraocular muscles themselves [
         <a href="#rid39">
          39,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The Charles Bonnet syndrome
         </strong>
         – The Charles Bonnet syndrome refers to the phenomenon of visual hallucinations in psychologically normal individuals who have visual loss due to lesions in either peripheral or central visual pathways. Its occurrence in GCA is rare [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Musculoskeletal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms of PMR occurring in a patient with GCA include characteristic proximal polyarthralgias and myalgias, sometimes accompanied by peripheral synovitis, and on occasion, distal extremity swelling with pitting edema (also known as remitting seronegative symmetrical synovitis with pitting edema [RS3PE]) [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">
          "Clinical manifestations and diagnosis of polymyalgia rheumatica", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H327457610">
         <span class="h2">
          Large vessel involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large vessel (LV) GCA refers to involvement of the aorta and its major proximal branches, especially in the
         <strong>
         </strong>
         upper extremities. The clinical consequences of LV GCA comprise aneurysms and dissections of the aorta, particularly the thoracic aorta, as well as stenosis, occlusion, and ectasia of large arteries. Subclinical LV GCA can also underlie systemic presentations of GCA, where fever and other constitutional symptoms predominate, without cranial symptomatology. (See
         <a class="local">
          'Constitutional symptoms'
         </a>
         above.)
        </p>
        <p>
         A variety of imaging modalities have demonstrated the frequency and extent of LV involvement  (
         <a class="graphic graphic_diagnosticimage graphicRef101604" href="/z/d/graphic/101604.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef101605" href="/z/d/graphic/101605.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef100635" href="/z/d/graphic/100635.html" rel="external">
          image 3
         </a>
         ). In a study of 35 consecutive patients with biopsy-proven GCA, fluorodeoxyglucose positron emission tomography (FDG-PET) showed vascular uptake of FDG at the subclavian arteries in 74 percent and at the thoracic aorta in 51 percent [
         <a href="#rid47">
          47
         </a>
         ]. Computed tomographic (CT) angiography of 40 patients with newly diagnosed, biopsy-proven GCA found evidence of arteritis in two-thirds of patients, mainly affecting the aorta (65 percent), but also affecting the brachiocephalic trunk (47 percent), subclavian arteries (42 percent), and femoral arteries (30 percent) [
         <a href="#rid48">
          48
         </a>
         ]. Studies using color-coded duplex ultrasonography have regularly identified involvement of the subclavian, axillary, or brachial arteries in at least 30 percent of patients with GCA [
         <a href="#rid49">
          49-51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">
          "Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Duplex ultrasound'
         </a>
         .)
        </p>
        <p>
         Symptomatically evident LV involvement is less commonly observed; a fair estimate of its incidence will require prospective studies incorporating standardized imaging protocols. But the clinical take-home point is important: Subclinical LV involvement is present in a significant percentage of patients with GCA.
        </p>
        <p>
         The clinical phenotype of LV-GCA differs somewhat from that of cranial arteritis. One study compared the clinical features of 74 patients with angiographically diagnosed subclavian or axillary involvement of GCA (or LV GCA) with those of 74 patients with biopsy-proven temporal artery GCA (or cranial artery GCA) [
         <a href="#rid52">
          52
         </a>
         ]. In contrast to those with cranial artery GCA, patients with LV GCA were younger at disease onset (66 versus 72 years), less likely to have headaches (14 versus 57 percent), and more likely to have arm claudication at presentation (51 versus 0 percent). Among the 57 patients with LV GCA in whom a temporal artery biopsy was eventually performed, positive biopsy findings were detected in only 33 patients (58 percent). Another larger retrospective study from the same tertiary care institution comparing 120 patients with radiographic evidence of subclavian artery vasculitis with 240 patents with positive temporal artery biopsies found similar results [
         <a href="#rid53">
          53
         </a>
         ]. The patients with LV vasculitis were younger (68 years versus 76 years), had a longer duration of symptoms prior to the diagnosis of GCA (median 3.5 months versus 2.2 months), fewer cranial symptoms (41 versus 83 percent), and less sight loss (4 versus 11 percent). Temporal artery biopsies, performed in 79 of the 120 patients with LV vasculitis, were positive in only one-half (52 percent).
        </p>
        <p>
         Clinical features of the cranial and LV phenotypes overlap. Systematic screening of patients with the cranial phenotype can demonstrate large artery involvement. On the other hand, temporal artery biopsies are positive in only approximately one-half of patients with LV GCA, underlining the essential role of imaging for the diagnosis of this phenotype. (See
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis", section on 'Evaluation for large vessel giant cell arteritis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic presentation of GCA
         </strong>
         – Systemic symptoms and signs can accompany the clinical presentation of both the cranial and LV phenotypes. Temporal artery biopsy or ultrasound is required to diagnose the former, imaging for the latter. In a study utilizing FDG-PET/CT for the evaluation of 240 patients with fever or inflammation of unknown origin, LV vasculitis accounted for 21 percent of 190 patients with a finalized diagnosis [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aortic aneurysm
         </strong>
         – The incidence of aortic aneurysms in GCA is heavily influenced by the methodologies used for detection and definition of aneurysms [
         <a href="#rid55">
          55
         </a>
         ]. Clinical recognition of aortic aneurysms/dilatation has been described in 10 to 20 percent of cases [
         <a href="#rid56">
          56-59
         </a>
         ], most studies favoring the lower figure. The thoracic aorta, especially the ascending aorta, is affected more often than the abdominal aorta. In these cases, there is often little or no clinical or laboratory evidence of systemic activity of GCA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Estimates of the magnitude of increased risk for aortic aneurysms in GCA compared with the general population vary. An early population-based cohort study of 96 patients with biopsy-proven GCA suggested that patients with GCA were 17 times more likely to develop thoracic aortic aneurysms and 2.4 times more likely to develop isolated abdominal aortic aneurysms than were persons of the same age and sex [
         <a href="#rid60">
          60
         </a>
         ]. Another study of a large database in the United Kingdom examined the cumulative incidence of aortic aneurysms based on diagnostic codes; while corroborating the increased risk of aortic aneurysms in patients with GCA, the relative risk of aortic aneurysms compared with controls was found to be 2.0 [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Aortic dilatation has been reported both in the early and late course of GCA (15 to 23 percent of newly diagnosed GCA patients and 22.2 and 33.3 percent of patients after a median disease duration of 5.4 and 10.3 years, respectively) [
         <a href="#rid48">
          48,58,62-64
         </a>
         ]. The time course between the diagnosis of the GCA and the discovery of aortic aneurysm varies, often depending on whether systematic imaging is obtained, but clinical recognition of an aortic aneurysm is delayed in the majority of patients. In a descriptive study of 41 patients with GCA who developed thoracic aortic aneurysms, three patients developed aneurysms before GCA was diagnosed, GCA and aneurysms were diagnosed simultaneously in five patients, and in the remaining 33 patients, aneurysms were detected a median of seven years after the diagnosis of GCA [
         <a href="#rid65">
          65
         </a>
         ]. Additional studies confirm that aortic aneurysm are a late complication of GCA, appearing 5 to 10 years after initial diagnosis [
         <a href="#rid16">
          16,56,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Histopathologic examination of specimens obtained from surgery or autopsy shows a range of findings, from fibrosis to varying degrees of active aortitis, including giant cells. These findings suggest two mechanisms of disease: chronic or late recrudescent aortitis causing elastin and collagen disruption, or mechanical stress on an aortic wall that had been weakened in the early active phase of the disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether the behavior of aneurysms in GCA resembles or differs from aneurysms of other etiologies is uncertain. One study has suggested that the rate of growth of aneurysms due to GCA is more rapid than those of degenerative etiology [
         <a href="#rid59">
          59
         </a>
         ]. Unfortunately for the clinician, predictive factors for the development of aortic aneurysms in GCA have not been clearly delineated. Inconsistencies in classification and data collection make it difficult to assign with confidence prognostic roles for age, sex, duration, and such traditional risk factors as smoking, hypertension, and hyperlipidemia. Aneurysms in GCA have not correlated with intensity and duration of glucocorticoid therapy [
         <a href="#rid16">
          16,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aortic dissection
         </strong>
         – While subclinical or clinical aortitis is common in GCA, the related major complications, namely aortic dissection and/or rupture, occur less frequently. In two retrospective studies from large referral centers, aortic dissection or rupture was identified in 1 and 6 percent of all patients with GCA [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Aortic dissection, which mainly affects the ascending thoracic aorta, can occur early or late in the course of disease. Aneurysm size does not appear to be a predictor of aortic dissection or rupture, while active aortitis may play a role [
         <a href="#rid59">
          59,66
         </a>
         ]. Although longevity in GCA is overall unaffected, epidemiologic data indicate that survival of the subset of patients with aortic aneurysm and dissection is decreased (standardized mortality ratio 2.63; 95% CI 1.78-3.73) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for aortic dissection due to GCA have not been clarified.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other large artery involvement
         </strong>
         – GCA can affect the subclavian arteries distal to the take-off of the vertebral arteries and extend through the axillary arteries to the proximal brachial arteries. Arterial bruits, diminished or absent blood pressures, and arm claudication can develop. Cold intolerance of the involved extremity is common, but explicit digital ulcerations and gangrene are rare because of adequate collateral arterial supply.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On imaging, upper-extremity arterial involvement in GCA is characteristically bilateral. Gradual tapering of vessels, with occasional occlusion, is typical  (
         <a class="graphic graphic_diagnosticimage graphicRef73553" href="/z/d/graphic/73553.html" rel="external">
          image 4
         </a>
         ) [
         <a href="#rid67">
          67
         </a>
         ]. The vessel wall is circumferentially affected, in contrast to the eccentric appearance of atherosclerosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinically evident lower-extremity arterial involvement can occur but is uncommon [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2025136927">
         <span class="h2">
          Less common manifestations
         </span>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Central nervous system involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stroke is uncommon in GCA. In descriptive cohorts, the frequency of stroke within the first four weeks of the diagnosis of GCA, and thus construed as potentially disease-related, has ranged from 1.5 to 7.5 percent [
         <a href="#rid27">
          27,69,70
         </a>
         ]. Clinical experience is most consistent with the lower end of these ranges.
        </p>
        <p>
         GCA is an unusual cause of ischemic stroke. In a population-based stroke registry, only 0.15 percent of 4086 cases of ischemic stroke satisfied criteria for the diagnosis of GCA [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Stroke due to GCA has two notable clinical features: Vertebrobasilar involvement is frequent, and intracranial involvement is rare [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Though strokes due to GCA can occur in the distribution of both the internal carotid and vertebrobasilar arteries, they are conspicuously more common in the latter location [
         <a href="#rid69">
          69,72,73
         </a>
         ]. More than one-half of strokes attributable to GCA occur in the vertebrobasilar system [
         <a href="#rid69">
          69,72
         </a>
         ]. This figure contrasts with population-based studies of transient ischemic attacks and stroke overall, which occur five times more often in the territory of the internal carotid arteries compared with the vertebrobasilar arteries [
         <a href="#rid74">
          74
         </a>
         ]. Arteritic involvement of the vertebral arteries can result in vertigo, ataxia, dysarthria, homonymous hemianopsia, or bilateral cortical blindness [
         <a href="#rid44">
          44
         </a>
         ]. Bilateral vertebral artery involvement, which causes rapidly progressive brainstem and/or cerebellar neurologic deficits with high mortality, is highly suggestive of GCA [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Documented involvement of intracranial vessels in GCA is limited [
         <a href="#rid44">
          44,76,77
         </a>
         ]. In 1 review of 463 patients with a clinical diagnosis of central nervous system vasculitis at the Mayo Clinic, only 2 patients had compelling evidence of intracranial GCA [
         <a href="#rid76">
          76
         </a>
         ]. In a subsequent case series of 185 patients with GCA evaluated at Mayo Clinic, 9 cases of GCA with intracranial involvement were identified [
         <a href="#rid77">
          77
         </a>
         ]. The major findings were a high incidence of neurologic deficits and poor prognosis despite treatment. Other clinical cases of intracranial involvement in the setting of GCA are described [
         <a href="#rid78">
          78
         </a>
         ], and 3 Tesla (3T) magnetic resonance imaging (MRI) has shown vessel wall enhancement of intradural arteries in a small number of GCA patients [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Though reported, other neurologic problems including peripheral neuropathy, myelopathy, higher cortical dysfunction or dementia, and pachymeningitis are uncommon complications of GCA [
         <a href="#rid80">
          80-82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H327458588">
         <span class="h3">
          Upper respiratory tract symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with GCA can present upper respiratory tract symptoms, in particular a nonproductive cough [
         <a href="#rid83">
          83
         </a>
         ]. The cause of cough is unknown, but may result from vasculitis in the area of cough receptors, which are located throughout the respiratory tree, or vasculitis of the ascending pharyngeal artery, a branch of the external carotid artery. Vasculitis of the bronchial arteries has been observed in the postmortem examination of a patient with disseminated GCA [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Other head and neck involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Branches of the external carotid artery are often affected in GCA  (
         <a class="graphic graphic_figure graphicRef50495" href="/z/d/graphic/50495.html" rel="external">
          figure 1
         </a>
         ), including the superficial temporal artery  (
         <a class="graphic graphic_figure graphicRef82875" href="/z/d/graphic/82875.html" rel="external">
          figure 2
         </a>
         ). Jaw claudication results from arteritic involvement of the muscles of mastication (masseter, temporalis, and medial and lateral pterygoid muscles), all of which are supplied by the branches of the external carotid artery. Involvement of other branches of the external carotid artery accounts for many of the other extracranial symptoms that can accompany the presentation of GCA, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maxillary and dental pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial swelling
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Throat pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tongue pain and macroglossia [
         <a href="#rid85">
          85
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Lingual infarction (causing ulceration of the tongue) and scalp necrosis are uncommon, owing to the rich collateral circulation of these tissues, but occasionally are seen, usually in neglected cases of longstanding duration [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H517921704">
         <span class="h3">
          Atypical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of unusual presentations of GCA have been reported, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysarthria [
         <a href="#rid88">
          88
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensorineural hearing loss [
         <a href="#rid89">
          89
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast mass [
         <a href="#rid90">
          90
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female genital tract involvement (ovary, fallopian tubes, or uterus; usually found by chance on histopathologic inspection of surgical specimens) [
         <a href="#rid91">
          91
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mesenteric ischemia [
         <a href="#rid92">
          92
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericarditis [
         <a href="#rid93">
          93
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          PHYSICAL EXAMINATION FINDINGS
         </span>
        </p>
        <p class="headingAnchor" id="H12737787">
         <span class="h2">
          Cardiovascular findings
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal pulses
         </strong>
         – In the setting of large vessel (LV) disease, diminished pulses and discrepant blood pressure in the arms can occur. On each visit, the carotid, brachial, radial, femoral, and pedal pulses should be palpated, and blood pressures in both arms measured.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Temporal artery abnormalities
         </strong>
         – The frontal or parietal branches of the superficial temporal arteries may be thickened, nodular, tender, or occasionally erythematous  (
         <a class="graphic graphic_picture graphicRef77618" href="/z/d/graphic/77618.html" rel="external">
          picture 1
         </a>
         ). Pulses may be decreased or absent. The occipital arteries and, less often, the postauricular or facial arteries may be enlarged or tender.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis performed to identify the utility of various clinical features in the diagnosis of GCA included 21 studies reported between 1996 and 2000 [
         <a href="#rid43">
          43
         </a>
         ]. The studies represented a total of 2680 patients who had undergone temporal artery biopsy, of whom 1050 (39 percent) had biopsy-proven GCA. Likelihood ratios (LR) for positive temporal artery biopsies were calculated for various features of the physical examination. The following observations were made:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A prominent or enlarged temporal artery – LR 4.3 (ie, a patient with such a finding was more than four times as likely to have a positive temporal artery biopsy than one without such a finding)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An absent temporal artery pulse – LR 2.7
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Temporal artery tenderness – LR 2.6
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Though these findings illustrate the potential value of the physical examination in evaluating patients with possible giant cell arteritis (GCA), in a sizeable number of patients with biopsy-proven GCA, clinical examination of the temporal arteries is unremarkable; conversely, prominence of the frontal branches of the temporal arteries in older adults is not infrequent or of pathologic consequence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bruits
         </strong>
         – Auscultation for bruits should be regularly performed. Bruits can be heard on auscultation of the carotid or supraclavicular areas, over the axillary, brachial, or femoral arteries, and over the abdominal aorta.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart murmur
         </strong>
         – Murmurs of aortic regurgitation may signal the development of an ascending aortic aneurysm with secondary dilatation of the aortic valve.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Ocular findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fundoscopy is indicated in patients with subjective change in visual acuity. In a patient with transient monocular visual loss (TMVL), the ophthalmologic examination can be entirely normal. Some patients have cotton wool spots in the retina, indicative of local, retinal ischemia, depending upon the site of critical vascular lesions.
        </p>
        <p>
         In patients with acute visual loss from arteritic anterior ischemic optic neuropathy (AION), ophthalmoscopic examination shows changes of ischemic optic neuropathy with a swollen pale disc and blurred margins  (
         <a class="graphic graphic_picture graphicRef70141" href="/z/d/graphic/70141.html" rel="external">
          picture 2
         </a>
         ). In patients with permanent visual loss, later findings include optic disc pallor.
        </p>
        <p>
         Fundoscopy can be valuable in differentiating nonarteritic AION from arteritic AION, as occurs in GCA. The affected swollen optic nerve is often pale immediately in GCA, whereas pallor is delayed in nonarteritic AION. The finding of associated retinal or choroidal ischemia in addition to AION is highly suggestive of GCA. Finally, the absence of a crowded optic disc in the unaffected eye of a patient with AION should make the diagnosis of nonarteritic AION unlikely and should increase the probability of arteritic AION [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         In posterior ischemic optic neuropathy (PION), acuity is reduced but the appearance of the optic nerve on ophthalmoscopic examination is normal in the acute phase because the ischemic insult has occurred well behind the optic disc. A relative afferent pupillary defect (APD), an objective means of identifying ipsilateral optic nerve dysfunction, will be present unless both eyes have symmetrical optic nerve dysfunction. In PION, the finding of an APD can be a useful sign to implicate optic neuropathy as a probable cause of visual loss even when the optic nerve appears normal.
        </p>
        <p>
         Diplopia is typically transient but if present, can be associated with reduced extraocular movements; diplopia due to a brainstem stroke results in skew deviation.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Musculoskeletal findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who also have polymyalgia rheumatica (PMR), active range of motion of the shoulders, neck, and hips can be limited, which in some patients can also be accompanied by distal synovitis, especially affecting the wrists and metacarpophalangeal joints. (See
         <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">
          "Clinical manifestations and diagnosis of polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h1">
          LABORATORY FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory findings useful in the assessment of giant cell arteritis (GCA) include routine hematologic testing, selected serum chemistry tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h2">
          Hematologic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         A normochromic anemia is often present prior to therapy and improves promptly after the institution of glucocorticoids. The anemia is occasionally profound [
         <a href="#rid94">
          94
         </a>
         ]. Many patients also have a reactive thrombocytosis [
         <a href="#rid95">
          95,96
         </a>
         ]. The leukocyte count is usually normal or minimally elevated, even in the setting of widespread systemic inflammation.
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h2">
          Erythrocyte sedimentation rate and C-reactive protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         A characteristic laboratory abnormality in many patients with GCA is a high ESR, which can reach 100 mm/hour [
         <a href="#rid43">
          43,96
         </a>
         ]. The CRP is nearly always commensurately elevated, though prospective head-to-head studies on the use of the ESR and CRP for the diagnosis and management of GCA are lacking. Among patients with a paraproteinemia or some other cause of a spuriously elevated or depressed ESR, the CRP level is more reliable. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants", section on 'Clinical use'
         </a>
         .)
        </p>
        <p>
         Less striking elevations of the ESR [
         <a href="#rid43">
          43
         </a>
         ], however, may also occur. In a population-based study of 167 patients from Olmsted County, 18 (11 percent) had an ESR less than 50 mm/hour and 9 (5 percent) less than 40 mm/hour before treatment was initiated. The patients with an ESR less than 40 mm/hour were less likely to experience systemic symptoms such as malaise, fever, or weight loss; nevertheless, their clinical manifestations, including risk of visual loss, were indistinguishable from those in patients with a higher ESR [
         <a href="#rid97">
          97
         </a>
         ]. In another series of 173 biopsy-proven cases, 12 patients (5.8 percent) had ESR values less than 46 mm/hour [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         An additional retrospective study from Olmsted County found normal values for both the ESR and CRP in 4 percent of 177 patients with biopsy-proven GCA at the time of diagnosis [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Neither the ESR nor the CRP is a specific biomarker for GCA. Abnormalities in the ESR and CRP can help calibrate the diagnostic probability of GCA, but normal values do not absolve the clinician of the responsibility to pursue the diagnosis in an appropriate clinical setting, nor do marked elevations certify that a diagnosis of GCA is correct. (See
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1733809369">
         <span class="h2">
          Other laboratory abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated serum concentrations of hepatic enzymes, especially the alkaline phosphatase, occur in 25 to 35 percent of patients. The elevations are typically modest and revert to normal with glucocorticoid therapy. The serum albumin level is often moderately decreased at diagnosis but responds quickly to the institution of glucocorticoids.
        </p>
        <p>
         Elevated serum interleukin (IL) 6 concentrations appear to be related closely to clinical disease activity in GCA [
         <a href="#rid100">
          100
         </a>
         ] and may better correlate with clinical relapse than the ESR [
         <a href="#rid101">
          101
         </a>
         ]. However, IL-6 assays are not routinely available, and their clinical utility remains unproven.
        </p>
        <p class="headingAnchor" id="H517919335">
         <span class="h1">
          IMAGING FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The posterior-anterior (PA) and lateral chest radiograph can show aneurysmal dilation of the ascending aorta, but has limited sensitivity. A detailed discussion of the other imaging modalities used to evaluate the extent of involvement of the aorta and large arteries is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8192.html" rel="external">
          "Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Imaging diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3343192058">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117108.html" rel="external">
          "Society guideline links: Giant cell arteritis and polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H43">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15532.html" rel="external">
          "Patient education: Polymyalgia rheumatica and giant cell arteritis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/579.html" rel="external">
          "Patient education: Vasculitis (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/576.html" rel="external">
          "Patient education: Polymyalgia rheumatica and giant cell arteritis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14404984">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – The major risk factor for developing giant cell arteritis (GCA, also known as Horton disease, cranial arteritis, and temporal arteritis) is aging. The disease almost never occurs before age 50 years, and its incidence rises steadily thereafter. Although systemic manifestations are characteristic of GCA and although vascular involvement can be widespread, clinical manifestations of the disease most frequently result from involvement of the cranial branches of arteries originating from the aortic arch. The most sinister complication of GCA, visual loss, is one potential result of the major phenotype of the disease, that of cranial arteritis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features and association with polymyalgia rheumatica
         </strong>
         – The onset of symptoms in GCA tends to be subacute, but abrupt presentations occur in some patients. When taking the patient's history, the clinician must ask about the following types of symptoms: systemic symptoms, such as fever, fatigue, and weight loss; headache; jaw claudication, which is the symptom most highly predictive of a positive temporal artery for the diagnosis of GCA; visual symptoms, particularly transient monocular visual loss (TMVL or amaurosis fugax) and diplopia; and symptoms of polymyalgia rheumatica (PMR). Other symptoms can also be present. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Association with polymyalgia rheumatica'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ocular involvement
         </strong>
         – A variety of ocular syndromes are associated with GCA. The most common are TMVL and anterior ischemic optic neuropathy (AION). It is estimated that bilateral blindness will develop in 25 to 50 percent of untreated patients who present with loss of vision in one eye. (See
         <a class="local">
          'Permanent vision loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Large vessel involvement
         </strong>
         – Subclinical involvement of the aorta and large arteries is frequent, a delayed clinical consequence of which can be aortic aneurysm. (See
         <a class="local">
          'Large vessel involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination findings
         </strong>
         – Careful temporal arteries palpation, measurement of the blood pressures in both arms, and assessment of the arterial tree by palpation and auscultation should be performed in all patients with suspected GCA. (See
         <a class="local">
          'Physical examination findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory findings
         </strong>
         – Laboratory findings useful in the assessment of GCA include routine hematologic testing, selected serum chemistry tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H799352315">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William P Docken, MD and James T Rosenbaum, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           González-Gay MA, García-Porrúa C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 1999; 78:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 2007; 86:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis 2010; 69:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garvey TD, Koster MJ, Crowson CS, Warrington KJ. Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. Semin Arthritis Rheum 2021; 51:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bas-Lando M, Breuer GS, Berkun Y, et al. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol 2007; 25:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol 2015; 42:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostberg G. An arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand Suppl 1973; 237:Suppl 237:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liozon E, Ouattara B, Rhaiem K, et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol 2009; 27:S89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001; 40:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill CL, Black RJ, Nossent JC, et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2017; 46:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Neogi T, Jick S. Mortality in Patients With Giant Cell Arteritis: A Cohort Study in UK Primary Care. Arthritis Care Res (Hoboken) 2018; 70:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013; 72:1989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005; 84:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981; 24:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JG. Clinical features of giant cell arteritis. Baillieres Clin Rheumatol 1991; 5:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996; 35:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabriel SE, O'Fallon WM, Achkar AA, et al. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Font C, Cid MC, Coll-Vinent B, et al. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997; 36:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-Gay MA, García-Porrúa C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004; 83:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005; 53:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JJ, Leavitt JA, Fang C, et al. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology 2016; 123:1999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott Med J 1979; 24:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano A, Muratore F, Pipitone N, et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 2017; 13:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liozon E, Dalmay F, Lalloue F, et al. Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients. J Rheumatol 2016; 43:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cid MC, Hernández-Rodríguez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nesher G, Nesher R, Mates M, et al. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 2008; 26:S30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller NR. Visual manifestations of temporal arteritis. Rheum Dis Clin North Am 2001; 27:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vodopivec I, Rizzo JF 3rd. Ophthalmic manifestations of giant cell arteritis. Rheumatology (Oxford) 2018; 57:ii63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biousse V, Newman NJ. Ischemic Optic Neuropathies. N Engl J Med 2015; 372:2428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS. Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye (Lond) 1990; 4 ( Pt 1):25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caselli RJ, Hunder GG. Neurologic complications of giant cell (temporal) arteritis. Semin Neurol 1994; 14:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002; 287:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972; 27:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razavi M, Jones RD, Manzel K, et al. Steroid-responsive charles bonnet syndrome in temporal arteritis. J Neuropsychiatry Clin Neurosci 2004; 16:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999; 42:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006; 55:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012; 71:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 2008; 47:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aschwanden M, Kesten F, Stern M, et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis 2010; 69:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford) 2012; 51:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999; 42:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 2015; 54:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schönau V, Vogel K, Englbrecht M, et al. The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis 2018; 77:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackie SL, Hensor EM, Morgan AW, Pease CT. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis 2014; 73:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48:3522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004; 83:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008; 59:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebed DT, Bois JP, Connolly HM, et al. Spectrum of Aortic Disease in the Giant Cell Arteritis Population. Am J Cardiol 2018; 121:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995; 122:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 2015; 74:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum 2008; 59:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Martínez A, Arguis P, Prieto-González S, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis 2014; 73:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muratore F, Crescentini F, Spaggiari L, et al. Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. Semin Arthritis Rheum 2019; 48:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 37:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermani TA, Warrington KJ, Crowson CS, et al. Predictors of Dissection in Aortic Aneurysms From Giant Cell Arteritis. J Clin Rheumatol 2016; 22:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermani TA, Matteson EL, Hunder GG, Warrington KJ. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol 2009; 36:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 2009; 48:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiszniewska M, Devuyst G, Bogousslavsky J. Giant cell arteritis as a cause of first-ever stroke. Cerebrovasc Dis 2007; 24:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988; 38:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boysson H, Liozon E, Larivière D, et al. Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study. J Rheumatol 2017; 44:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turney TM, Garraway WM, Whisnant JP. The natural history of hemispheric and brainstem infarction in Rochester, Minnesota. Stroke 1984; 15:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rüegg S, Engelter S, Jeanneret C, et al. Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature. Medicine (Baltimore) 2003; 82:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Giannini C, Miller DV, Hunder G. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum 2006; 55:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez-Alvarez C, Hawkins AS, Koster MJ, et al. Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement. ACR Open Rheumatol 2020; 2:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsolaimani RS, Bhavsar SV, Khalidi NA, et al. Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol 2016; 43:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siemonsen S, Brekenfeld C, Holst B, et al. 3T MRI reveals extra- and intracranial involvement in giant cell arteritis. AJNR Am J Neuroradiol 2015; 36:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am 1993; 19:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 1988; 38:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uribe JA, Aggarwal I, Witthayaweerasak J, et al. Refractory Giant Cell Arteritis Complicated by Vision Loss From Optic Atrophy and Maculopathy Associated With Pachymeningitis. J Neuroophthalmol 2018; 38:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larson TS, Hall S, Hepper NG, Hunder GG. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 1984; 101:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sendino A, Barbado FJ, González-Anglada I, et al. Temporal arteritis: a form of systemic panarteritis. Ann Rheum Dis 1992; 51:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helfrich DJ, Mulhern LM, Luparello FJ, Smith W Jr. Giant cell arteritis of the tongue presenting as macroglossia. J Rheumatol 1988; 15:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsianakas A, Ehrchen JM, Presser D, et al. Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. J Am Acad Dermatol 2009; 61:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodmann M, Dorr A, Hafner F, et al. Tongue necrosis as first symptom of giant cell arteritis (GCA). Clin Rheumatol 2009; 28 Suppl 1:S47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CC, Su WW, Hunder GG. Dysarthria associated with giant cell arteritis. J Rheumatol 1999; 26:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amor-Dorado JC, Llorca J, Garcia-Porrua C, et al. Audiovestibular manifestations in giant cell arteritis: a prospective study. Medicine (Baltimore) 2003; 82:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández-Rodríguez J, Tan CD, Molloy ES, et al. Vasculitis involving the breast: a clinical and histopathologic analysis of 34 patients. Medicine (Baltimore) 2008; 87:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajocchi G, Zamorani G, Cavazza A, et al. Giant-cell arteritis of the female genital tract associated with occult temporal arteritis and FDG-PET evidence of large-vessel vasculitis. Clin Exp Rheumatol 2007; 25:S36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scola CJ, Li C, Upchurch KS. Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation. Medicine (Baltimore) 2008; 87:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bablekos GD, Michaelides SA, Karachalios GN, et al. Pericardial involvement as an atypical manifestation of giant cell arteritis: report of a clinical case and literature review. Am J Med Sci 2006; 332:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss LM, Gonzalez E, Miller SB, Agudelo CA. Severe anemia as the presenting manifestation of giant cell arteritis. Arthritis Rheum 1995; 38:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foroozan R, Danesh-Meyer H, Savino PJ, et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 2002; 109:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005; 84:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum 2001; 45:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liozon E, Jauberteau-Marchan MO, Ly K, et al. Giant cell arteritis with a low erythrocyte sedimentation rate: comments on the article by Salvarani and Hunder. Arthritis Rheum 2002; 47:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012; 41:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43:1041.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8225 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10499071" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21360492" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790127" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Epidemiology of giant cell arteritis and polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15077270" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17435586" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19854712" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Increase in age at onset of giant cell arteritis: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34644662" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428357" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2003856" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25362658" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Projected worldwide disease burden from giant cell arteritis by 2050.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4151114" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : An arteritis with special reference to polymyalgia arteritica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19646354" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709607" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28040246" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29409137" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mortality in Patients With Giant Cell Arteritis: A Cohort Study in UK Primary Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23253927" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16148727" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7317119" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8227892" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fever of unknown origin in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1807819" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical features of giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8948307" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7699690" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8479714" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Visual prognosis in giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9133940" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11039076" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11530032" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028965" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk factors for cranial ischemic complications in giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818722" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27297405" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15885780" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Poor prognosis of visual outcome after visual loss from giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/493941" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Temporal arteritis. A 14-year epidemiological, clinical and prognostic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28680132" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Visual loss and other cranial ischaemic complications in giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27134245" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9433866" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270860" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18799050" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11723764" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Visual manifestations of temporal arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9559737" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Ocular manifestations of giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29986083" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ophthalmic manifestations of giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26083207" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ischemic Optic Neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2323477" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7709085" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Neurologic complications of giant cell (temporal) arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11754714" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Does this patient have temporal arteritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5078894" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15616179" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Steroid-responsive charles bonnet syndrome in temporal arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10366120" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16463425" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22267328" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18077499" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20498213" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22179725" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10025926" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Disease pattern in cranial and large-vessel giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25193809" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Large-vessel giant cell arteritis: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28928271" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23264356" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14674004" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15525845" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18311764" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29291886" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Spectrum of Aortic Disease in the Giant Cell Arteritis Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7872584" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24095936" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438900" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23873881" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30424972" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7864947" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27219304" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Predictors of Dissection in Aortic Aneurysms From Giant Cell Arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1200525" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Large artery involvement in giant cell (temporal) arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19755612" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Symptomatic lower extremity vasculitis in giant cell arteritis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593228" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19109317" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630482" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Giant cell arteritis as a cause of first-ever stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3347337" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Neurologic disease in biopsy-proven giant cell (temporal) arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28089985" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6474528" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The natural history of hemispheric and brainstem infarction in Rochester, Minnesota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12544706" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17139651" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Giant cell arteritis: Involvement of intracranial arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32697426" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26773119" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Severe intracranial involvement in giant cell arteritis: 5 cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25169925" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : 3T MRI reveals extra- and intracranial involvement in giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8265830" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Neurologic aspects of giant cell (temporal) arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2834668" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Peripheral neuropathic syndromes in giant cell (temporal) arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29059089" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Refractory Giant Cell Arteritis Complicated by Vision Loss From Optic Atrophy and Maculopathy Associated With Pachymeningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6486590" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Respiratory tract symptoms as a clue to giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1417143" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Temporal arteritis: a form of systemic panarteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3418626" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Giant cell arteritis of the tongue presenting as macroglossia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19577329" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19277817" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Tongue necrosis as first symptom of giant cell arteritis (GCA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10229420" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Dysarthria associated with giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12544707" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Audiovestibular manifestations in giant cell arteritis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344804" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Vasculitis involving the breast: a clinical and histopathologic analysis of 34 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428363" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Giant-cell arteritis of the female genital tract associated with occult temporal arteritis and FDG-PET evidence of large-vessel vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18204370" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17031245" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Pericardial involvement as an atypical manifestation of giant cell arteritis: report of a clinical case and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7880198" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Severe anemia as the presenting manifestation of giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093648" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Thrombocytosis in patients with biopsy-proven giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16148728" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11324777" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522849" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Giant cell arteritis with a low erythrocyte sedimentation rate: comments on the article by Salvarani and Hunder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22119103" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8216422" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10817557" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
